ImmunoGen,Inc. (NASDAQ:IMGN) Files An 8-K Other Events

32

ImmunoGen,Inc. (NASDAQ:IMGN) Files An 8-K Other Events
ITEM 8.01. OTHER EVENTS

On October11, 2017,ImmunoGen,Inc. (the “Company”) issued a press release announcing that it had closed its previously announced public offering of 16,675,000 shares of its common stock at a public offering price of $6.50 per share. The Company sold an aggregate of 16,675,000 shares of its common stock, including 2,175,000 shares of common stock issued upon the exercise in full by the underwriters of their option to purchase additional shares, with net proceeds to the Company of approximately $101.6 million, after deducting underwriting discounts and estimated offering expenses. The Company’s press release is filed as Exhibit99.1 to this Current Report on Form8-K and is incorporated herein by reference.

ITEM 9.01. FINANCIAL STATEMENTS AND EXHIBITS

(d): The following exhibit is being filed herewith:


IMMUNOGEN INC Exhibit
EX-99.1 2 a17-23084_1ex99d1.htm EX-99.1 Exhibit 99.1     News Release   IMMUNOGEN ANNOUNCES CLOSING OF PUBLIC OFFERING OF COMMON STOCK,…
To view the full exhibit click here

About ImmunoGen,Inc. (NASDAQ:IMGN)

ImmunoGen, Inc. is a clinical-stage biotechnology company that develops targeted cancer therapeutics using its antibody-drug conjugate (ADC) technology. The Company is engaged in the discovery of monoclonal antibody-based anticancer therapeutics. An ADC with the Company’s technology comprises an antibody that binds to a target found on tumor cells conjugated to one of its anti-cancer agents as a payload to kill the tumor cell once the ADC has bound to its target. Its product candidates include Mirvetuximab soravtansine; IMGN779; IMGN632; IMGN529, and Coltuximab ravtansine. Its portfolio is led by Mirvetuximab soravtansine, a first-in-class ADC targeting folate-receptor alpha (Fra). Its FORWARD II consists of cohorts assessing Mirvetuximab soravtansine in combination with, in separate doublets, Avastin (bevacizumab), pegylated liposomal doxorubicin (PLD), and carboplatin. The Company has developed tubulin-acting maytansinoid payload agents, which include DM1 and DM4.

An ad to help with our costs